The deal is done
A life-extending drug is now available in England. It is for breast cancer. The drug, called Enhertu, will be offered on the National Health Service after ministers and its manufacturers finally reached a commercial agreement on its price. This deal brings an end to a delay that lasted more than two years, a period during which English patients could not access a treatment that was already being prescribed just across the border in Scotland. For thousands of women, the wait is over. The treatment starts on Thursday.
The drug targets a specific form of the disease. It helps women with HER2-low advanced breast cancer, a diagnosis that previously carried a much bleaker prognosis with fewer treatment options. Around one thousand women a year in England fall into this category and will now be eligible for the new therapy. They will live longer. The average is seven months. Seven months is a profoundly meaningful amount of time for patients with an incurable illness, giving them an opportunity to reach milestones or simply spend more time with their loved ones. This time was previously denied.
The new deal highlights a deep disparity within the United Kingdom's health systems. A postcode lottery was at play. While women in England waited for negotiations to conclude, doctors in Scotland were already prescribing Enhertu. The situation lasted two years. The Scottish Medicines Consortium, the body that approves drugs for use in Scotland's NHS, had authorised the treatment long before its English counterpart would give the final go-ahead. It meant that a woman's access to a life-extending cancer drug depended entirely on which part of the country she happened to live in, a difficult reality for those south of the border who knew a better option existed.
The deadlock in England was broken this week. It was all about money. A successful conclusion to price negotiations between the government and the drug’s makers was the single factor that unlocked NHS access for these thousands of patients. The precise details of the deal, including the final cost per dose agreed with the pharmaceutical companies, have not been made public. Such commercial arrangements are almost always confidential. The result, however, is not. A vital new treatment is now on the formulary.
How the drug works
All breast cancers are tested for a protein. It is called HER2. Some tumours have high levels of this protein, making them HER2-positive. Others have none at all. They are HER2-negative. A very large group of patients exists between these two states. Their cancer expresses some HER2 protein, but not enough to be classified as HER2-positive. This is HER2-low breast cancer. For years, this classification offered little hope, as these patients were treated like HER2-negative cases and given fewer, often less effective, therapeutic options.
Enhertu changes this. It works in a completely different way from traditional chemotherapy. The drug is an advanced therapy, best understood as a form of biological missile. It is composed of two distinct and vital components, an antibody that functions as a highly specialised guidance system and a potent chemotherapy drug attached as its payload. The antibody has one job. It is engineered to seek out and bind only to the HER2 protein found on the surface of the cancer cells. This is its target.
The process is precise. The drug circulates in the patient's bloodstream, ignoring most healthy cells which lack the specific HER2 marker it is searching for. It is a quiet hunt. Once the antibody finds a cancer cell and locks onto its target protein, the cell itself absorbs the entire complex. It is a Trojan horse mechanism. Only after it is safely inside the cancer cell is the toxic chemotherapy payload released, destroying the malignant cell directly from within. This is targeted destruction.
The result is that the full force of the chemotherapy is unleashed inside the tumour, rather than being diffused throughout the body. This precision helps to minimise the collateral damage to healthy tissues that causes many of the severe side effects associated with older, untargeted cancer treatments. It is this sensitivity that makes Enhertu a breakthrough for the HER2-low patient group. The drug is effective even with low levels of the target protein, something previous HER2-targeted drugs could not achieve. It reclassifies what was a diagnostic dead end into a treatable condition, offering a new path forward for women who had few remaining choices.
The price of seven months
The drug was effective. That was not the issue. The issue was its price. For patients in England, the delay was about money.
The National Institute for Health and Care Excellence, or NICE, is the body that decides which new treatments are made available on the NHS in England. It has a strict remit. It must balance the clinical benefit of a drug against its cost to the taxpayer. NICE calculates value for money. The core function of the institute is to determine if the additional months or quality of life a treatment offers are proportional to the money the health service would have to spend to provide it. For Enhertu, the initial judgement was that the price demanded by its manufacturers was simply too high for the average seven months of extra life it offered.
The answer was no.
This rejection was not an end point. It was the beginning of a long negotiation. Talks opened between NHS England, the government, and the drug's makers. These discussions are commercial and confidential. They happened behind closed doors. For two years, while the drug was being prescribed in Scotland, officials in England argued over the price per dose. The system is designed to force manufacturers to lower their costs for the large market the NHS represents, but the process can be slow, leaving patients waiting for a financial agreement to be reached. This was a standoff.
A deal was finally struck this month. The breakthrough came after the manufacturers agreed to a substantial, though undisclosed, discount. This confidential arrangement allows the NHS to pay a lower, more sustainable price while the manufacturer can maintain a higher official list price for the drug in other countries, a common practice in complex pharmaceutical negotiations. With this new price on the table, NICE could reassess its calculations. The cost now fit the benefit. The drug was approved. This is why women in England can get the treatment from this week. The barrier was financial, and it has, for now, been removed.
A tale of two health systems
In Scotland, Enhertu has been available for more than two years. The drug was approved there. The Scottish Medicines Consortium, the body which assesses new medicines for NHS Scotland, gave the green light long before its English counterpart. Its decision meant that oncologists from Dumfries to Dundee could prescribe the treatment. This created a stark divergence. Patients in England were left waiting while the National Institute for Health and Care Excellence continued its own separate, and much longer, appraisal process which was fundamentally tied to reaching a lower price agreement with the manufacturers. The systems are different. The outcomes are different too.
This is the effect of devolved healthcare. Four nations. Four systems. What is available on the NHS in one part of the United Kingdom is not always available in another, creating a situation often described as a postcode lottery. It is a lottery of life and death. The practical reality of this for about 1,000 women a year was that their access to a life extending drug depended entirely on which side of the Anglo Scottish border they lived. A diagnosis in Carlisle meant a different clinical pathway from a diagnosis just a few miles north in Gretna. The biology was identical. The bureaucracy was not.
The Scottish Medicines Consortium and NICE operate independently. They use similar data but can reach different conclusions, often based on their distinct methods for assessing value for money and their respective negotiation strategies with pharmaceutical firms. Scotland's quicker approval does not mean its process is less rigorous. It was a different calculation. Assessors there reached a different agreement on price, or perhaps they placed a different value on the seven additional months of life the drug offered patients with incurable cancer. The exact details of the Scottish deal, like the new English one, are confidential. What is clear is that a resolution was found in Edinburgh years before one was reached in London. Two years earlier.
The two year delay highlights a fundamental tension within the structure of the UK's public health provision, where national bodies can create regional inequalities in care for identical conditions. This is not a new problem. The case of Enhertu is just one specific, and for patients in England, painful example of how the system works. The gap is now closed. From this week, access to Enhertu is harmonised across the two countries, not because of a change in medical evidence but because a financial negotiation finally concluded. For the women who will now receive the drug in England, the wait is over. For others, it was too long.
What happens now
The wait ends this week. From Thursday, Enhertu will be available on the NHS in England. This is the new reality. Around 1,000 women a year are expected to be eligible for the treatment, a figure which illustrates the scale of need for this specific form of incurable breast cancer. The decision immediately changes the conversations happening in oncology clinics up and down the country, transforming the outlook for patients who had previously exhausted their treatment options. Doctors have a new tool. A new hope to offer.
The process is medically directed. It begins with the oncologist. They will review their patient lists to identify women with a confirmed diagnosis of HER2-low advanced breast cancer who might benefit from this specific biological therapy. These are women for whom the cancer has spread and is no longer considered curable, but whose disease can be managed and whose lives can be prolonged. A consultation will confirm a patient meets the precise clinical criteria established by NICE, the health regulator which has now approved the drug following the successful price negotiation. The prescription is then written. The treatment itself is administered intravenously, a procedure that must take place in a hospital chemotherapy unit under specialist supervision.
For NHS trusts, the change requires immediate action. They must now ensure the drug is in stock and that pharmacy and nursing staff are prepared to manage and administer it according to the newly issued national guidelines. It is a logistical exercise. Local health budgets will need to be adjusted to account for the new, confidential price that the government has agreed with the drug's manufacturers. Clinical pathways, the formal documents that map out a patient's journey through the complex stages of cancer treatment, will be redrafted to include Enhertu as a standard option following certain other therapies. For the women affected, this bureaucratic shift is everything. It is another seven months of life, on average. The change is not theoretical. It is practical. It is happening now.
The next negotiation is already starting
The Enhertu deal is done. For around one thousand women a year, this is life changing news. But this is not an isolated event. This is a recurring pattern. The fight over Enhertu’s price is simply the latest example of a constant, difficult negotiation at the heart of the National Health Service. Another is already beginning for a different drug, a different condition, a different group of patients waiting for hope. The system is designed for this conflict.
The roles are clearly defined. Pharmaceutical companies develop and patent new medicines, often after investing hundreds of millions of pounds over many years, and they set an initial list price designed to secure a return. Then the National Institute for Health and Care Excellence, the health technology watchdog for England, performs its calculation. NICE weighs the extra months or years of life a drug might offer against its cost, deciding if it represents value for the taxpayer's money. The maths is brutal. The answer is often no.
When NICE rejects a drug, the negotiation begins in earnest. This is what happened with Enhertu. The process can take months or, as in this case, years. Campaigners lobby. Doctors write letters. Patients speak to the media about being denied a treatment available in other countries. Behind closed doors, NHS England’s commercial team and the drug’s manufacturer haggle over the final price, seeking a confidential discount that allows NICE to reverse its decision without the company lowering its public list price elsewhere. A life has a price. The negotiation is about finding it. The two year wait for English patients shows the human cost of these protracted commercial discussions.
This model creates a predictable drama. It also creates deep uncertainty for people who are terminally ill. The successful deal for Enhertu offers a template for what is to come as medical science produces ever more sophisticated, and expensive, treatments for conditions like cancer. The next generation of therapies, including personalised gene treatments, will carry price tags that make Enhertu look modest, posing an even greater challenge to the founding principle of an NHS free at the point of use. The pressure will be immense. The government will face it. NICE will run the same numbers. The debate over what a society is willing to pay for extra months of life is not over. It is a permanent fixture.
Sources. BBC News Health: New hope for breast cancer patients as life-extending drug now on NHS in England. Guardian UK: Women in England with incurable breast cancer to get life-extending drug on NHS.
Analysis. Drafted with AI assistance from the sources listed above and reviewed by an editor before publication. Jnews links to the organisations it writes about.
